Article
Psychology, Clinical
Lenard A. Adler, Terry L. Leon, Taylor M. Sardoff, Beth Krone, Stephen Faraone, Michael J. Silverstein, Jeffrey H. Newcorn
Summary: The study investigated the efficacy of LDX versus placebo in treating adults with ADHD and SCT through a randomized crossover trial. It found that LDX significantly improved SCT, ADHD, executive function deficits, and functional impairment ratings compared to placebo.
JOURNAL OF CLINICAL PSYCHIATRY
(2021)
Article
Pediatrics
Amirmohammad Tajik, Shekoufeh Nikfar, Sepideh Elyasi, Omid Rajabi, Mehdi Varmaghani
Summary: LDX therapy for ADHD is associated with higher costs but appears to be a cost-effective choice compared to MPH, based on the Incremental Cost-Effectiveness Ratio (ICER) and probabilities calculated in the study. Incorporating LDX into Iran's healthcare system may result in a financial burden initially, but could provide benefits over time in managing ADHD.
CHILD AND ADOLESCENT PSYCHIATRY AND MENTAL HEALTH
(2023)
Article
Multidisciplinary Sciences
Sneha M. Vaddadi, Nicholas J. Czelatka, Belsy D. Gutierrez, Bhumika C. Maddineni, Kenneth L. McCall, Brian J. Piper
Summary: In recent years, the use of prescription stimulants in the United States has been increasing, particularly for amphetamine and lisdexamfetamine. The study found that the usage of stimulants in the Western region was lower compared to other regions, and areas with a higher percentage of Hispanic populations also had lower stimulant usage.
Article
Psychology, Developmental
Karen Vertessen, Marjolein Luman, James M. Swanson, Marco Bottelier, Reino Stoffelsen, Pierre Bet, Annemiek Wisse, Jos W. R. Twisk, Jaap Oosterlaan
Summary: Methylphenidate (MPH) has been proven effective in treating ADHD symptoms in children. However, the relationship between dosage and symptom control varies greatly among individuals and the placebo effect also plays a role.
EUROPEAN CHILD & ADOLESCENT PSYCHIATRY
(2023)
Article
Psychology, Developmental
Ann C. Childress, Eric Lloyd, Leslie Jacobsen, Lhanoo Gunawardhana, Steven A. Johnson, Robert L. Findling
Summary: This study evaluated the acute efficacy, safety, and tolerability of lisdexamfetamine dimesylate (LDX) vs placebo (PBO) in preschool-aged children with attention-deficit/hyperactivity disorder (ADHD). LDX was found to be more effective than PBO in reducing symptoms and was generally well tolerated.
JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY
(2022)
Review
Biochemistry & Molecular Biology
Stephen Faraone, Jeffrey H. Newcorn, Andrea Cipriani, Daniel Brandeis, Anna Kaiser, Sarah Hohmann, Alexander Haege, Samuele Cortese
Summary: The study analyzed the placebo and nocebo effects in ADHD medications, finding significant impact of placebo effects on efficacy and negative effects on tolerability. It also discovered a positive correlation between baseline to endpoint placebo effects and drug effects.
MOLECULAR PSYCHIATRY
(2022)
Article
Pediatrics
Ann C. Childress, Eric Lloyd, Steven A. Johnson, Lhanoo Gunawardhana, Valerie Arnold
Summary: This study evaluated the long-term safety and tolerability of lisdexamfetamine dimesylate (LDX) in preschool-aged children (4-5 years old) with attention-deficit/hyperactivity disorder (ADHD). The results showed that the optimized dosage of LDX (5-30 mg) was well tolerated and led to reductions in ADHD symptoms compared to baseline.
JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY
(2022)
Article
Psychiatry
Jose Ramon Gutierrez-Casares, Javier Quintero, Guillem Jorba, Valentin Junet, Vicente Martinez, Tamara Pozo-Rubio, Baldomero Oliva, Xavier Daura, Jose Manuel Mas, Carmen Montoto
Summary: This study established models based on systems biology, completed a virtual clinical trial through three phases, and compared two treatments for attention-deficit/hyperactivity disorder. The results showed that conducting clinical trials using computer technology can greatly reduce costs and time, providing possibilities for the development of personalized medicine.
FRONTIERS IN PSYCHIATRY
(2021)
Article
Neurosciences
Jose Ramon Gutierrez-Casares, Cristina Segu-Verges, Juncal Sabate Chueca, Tamara Pozo-Rubio, Mireia Coma, Carmen Montoto, Javier Quintero
Summary: Attention-deficit/hyperactivity disorder (ADHD) is a psychiatric condition that can continue into adulthood and is often accompanied by other psychiatric comorbidities. Lisdexamfetamine (LDX) is a stimulant prodrug approved for treating ADHD and binge eating disorder (BED). Through a computational model, we evaluated the efficacy of a virtual model of LDX (vLDX) as ADHD treatment in improving five common ADHD psychiatric comorbidities in adults and children, and explored the molecular mechanisms underlying the predicted efficacy of LDX.
FRONTIERS IN NEUROSCIENCE
(2023)
Article
Pediatrics
Luisa Shiguemi Sugaya, Giovanni Abrahao Salum, Wagner de Sousa Gurgel, Erika Mendonca de Morais, Giovana Del Prette, Caroline Drehmer Pilatti, Bianca Batista Dalmaso, Ellen Leibenluft, Luis Augusto Rohde, Guilherme Vanoni Polanczyk
Summary: This study found that methylphenidate and behavioral parent training have significant effects in reducing symptoms and improving functionality for preschool children aged 3-5 with ADHD after 8 weeks of treatment.
LANCET CHILD & ADOLESCENT HEALTH
(2022)
Review
Psychology, Multidisciplinary
Kirsty Lauder, Almuth McDowall, Harriet R. R. Tenenbaum
Summary: ADHD has a significant impact on the global workforce, yet little is known about how best to support ADHDers in the workplace. Current research primarily focuses on pharmacological interventions, while key mechanisms of effectiveness come from psychosocial interventions such as group therapy.
FRONTIERS IN PSYCHOLOGY
(2022)
Article
Pediatrics
Yu-Shu Huang, Chin-Bin Yeh, Chin-Hung Chen, Chi-Yung Shang, Susan Shur-Fen Gau
Summary: The study investigated the efficacy and safety of a new formulation ORADUR-MPH in children and adolescents with ADHD, showing that it is more effective than placebo in reducing ADHD symptoms and is well-tolerated with the main side effect being decreased appetite.
JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY
(2021)
Article
Psychology, Developmental
Jeanette M. Johnstone, Irene Hatsu, Gabriella Tost, Priya Srikanth, Leanna P. Eiterman, Alisha M. Bruton, Hayleigh K. Ast, Lisa M. Robinette, Madeline M. Stern, Elizabeth G. Millington, Barbara L. Gracious, Andrew J. Hughes, Brenda M. Y. Leung, L. Eugene Arnold
Summary: This study evaluated whether micronutrients (vitamins/minerals) benefit ADHD and irritability in a North American pediatric sample. The results showed that micronutrients demonstrated overall benefit over placebo according to blinded clinician ratings, but did not show significant differences in parent-report composite ratings. Additionally, the micronutrient group had greater height growth.
JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY
(2022)
Review
Pharmacology & Pharmacy
Louise Carton, Romain Icick, Sebastien Weibel, Maurice Dematteis, Etienne Kammerer, Anne Batisse, Benjamin Rolland
Summary: Lisdexamfetamine dimesylate (LDX) is a prodrug used for the treatment of attention deficit/hyperactivity disorder and binge eating disorder in adults in some countries. This review aimed to determine the abuse potential of LDX in adults through various studies. Most studies suggested that LDX has a delayed onset of effects and decreased euphoria compared to immediate-release dexamphetamine. The prodrug property of LDX also limits its potential for abuse. Epidemiological studies found that LDX abuse rates were lower than those of immediate-release dexamphetamine. However, more long-term pharmaco-epidemiological studies are needed to confirm these findings.
EXPERT REVIEW OF CLINICAL PHARMACOLOGY
(2022)
Article
Health Care Sciences & Services
Mohammad Haghighi, Mona Doostizadeh, Leila Jahangard, Alireza Soltanian, Mohammad Faryadres, Kenneth M. Duersteler, Annette Beatrix Bruehl, Dena Sadeghi-Bahmani, Serge Brand
Summary: Among male adults in stable marital relationships with regular weekly penile-vaginal intercourse, lisdexamfetamine dimesylate improved dimensions of early ejaculation. However, improvements were also observed in the placebo condition, indicating the potential influence of psychological factors.